![share_log](https://pubimg.futunn.com/201912120187256955015721ae9.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Altimmune | 10-Q: Q1 2024 Earnings Report
Altimmune | 10-Q: Q1 2024 Earnings Report
Altimmune | 10-Q:2024財年一季報
牛牛AI助理已提取核心訊息
Altimmune, a clinical stage biopharmaceutical company, reported a net loss of $24.394 million for the first quarter ended March 31, 2024, a 22% increase from the $20.074 million loss in the same period last year. Revenue for the quarter was negligible at $5,000, down 76% from $21,000 in the previous year, attributed to the final indirect rate adjustments of closed contracts. Operating expenses rose by 23% to $26.799 million, driven by a 25% increase in research and development costs, which totaled $21.487 million. This increase was primarily due to the ramp-up of the IMPACT Phase 2b trial in MASH and manufacturing expenses for pemvidutide. General and administrative expenses also grew by 17% to $5.312 million, mainly due to higher stock compensation and professional fees. Interest income provided a positive impact, increasing by 45% to $2.413 million...Show More
Altimmune, a clinical stage biopharmaceutical company, reported a net loss of $24.394 million for the first quarter ended March 31, 2024, a 22% increase from the $20.074 million loss in the same period last year. Revenue for the quarter was negligible at $5,000, down 76% from $21,000 in the previous year, attributed to the final indirect rate adjustments of closed contracts. Operating expenses rose by 23% to $26.799 million, driven by a 25% increase in research and development costs, which totaled $21.487 million. This increase was primarily due to the ramp-up of the IMPACT Phase 2b trial in MASH and manufacturing expenses for pemvidutide. General and administrative expenses also grew by 17% to $5.312 million, mainly due to higher stock compensation and professional fees. Interest income provided a positive impact, increasing by 45% to $2.413 million. The company's cash position remains strong with $182.1 million in cash, cash equivalents, and short-term investments, which is expected to fund operations through 2024 and 2025. Altimmune's lead product candidate, pemvidutide, showed promising results in a Phase 2 obesity trial, with significant weight loss attributed to adipose tissue reduction. However, development of HepTcell has ceased due to insufficient response in its Phase 2 trial. Looking forward, Altimmune will continue to seek additional financing and partnership opportunities to support its clinical trials and research activities.
臨床醫學生物製藥公司Altimmune報告稱,截至2024年3月31日的第一季度淨虧損爲2439.4萬美元,比去年同期的2007.4萬美元的虧損增加了22%。該季度的營業收入爲5,000美元,較上年的21,000美元下降了76%,歸因於已關閉合同的最終間接費率調整。營業費用增長了23%,達到2679.9萬美元,其中研發費用增長了25%,達到2148.7萬美元。這種增長主要是由於在MASH推出IMPACt第20億試驗和pemvidutide的製造費用上的增加。一般和行政費用也增長了17%,達到531.2萬美元,主要是由於更高的股票補償和專業費用。利息收益帶來了積極影響,增長了45%,達到241....展開全部
臨床醫學生物製藥公司Altimmune報告稱,截至2024年3月31日的第一季度淨虧損爲2439.4萬美元,比去年同期的2007.4萬美元的虧損增加了22%。該季度的營業收入爲5,000美元,較上年的21,000美元下降了76%,歸因於已關閉合同的最終間接費率調整。營業費用增長了23%,達到2679.9萬美元,其中研發費用增長了25%,達到2148.7萬美元。這種增長主要是由於在MASH推出IMPACt第20億試驗和pemvidutide的製造費用上的增加。一般和行政費用也增長了17%,達到531.2萬美元,主要是由於更高的股票補償和專業費用。利息收益帶來了積極影響,增長了45%,達到241.3萬美元。公司的現金頭寸仍然強勁,現金、現金等價物和短期投資總計18210萬美元,預計可以支持運營至2024年和2025年。Altimmune的主導產品候選者pemvidutide在第二期肥胖症試驗中顯示出有希望的結果,體重減輕歸因於脂肪組織減少。然而,在其第二期試驗中,HepTcell的開發因反應不足而停止。展望未來,Altimmune將繼續尋求額外的融資和合作機會,以支持其臨床試驗和研究活動。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了